RxDoctor Payments DataLook up a doctor →

Ashish Saharia, MD

Surgery · Sugar Land, TXNPI 1821241571

Payments from drug & device makers

$465,912in general payments, 2019–2025

Across 271 payments — averaging $1719.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Transmedics, Inc.$405K
  • Takeda Pharmaceuticals U.S.A., Inc.$30K
  • Paragonix Technologies, Inc.$13K
  • Intuitive Surgical$8K
  • Shire North American Group Inc$3K
  • Boston Scientific$2K
  • plus $5K from 36 others

What the payments were for

  • Travel & lodging$9376%
  • Food & beverage$6,79243%
  • Education$8,00051%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$465,912 in reported general payments places this provider in the 95th percentile of 1,830 surgery providers in Texas.

See all surgery providers in Texas

Medicare billing

Part B allowed, 2024
$109,114
Medicare patients
109
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atovaquone149$106,178
Everolimus39$99,547
Tacrolimus360$58,254
Ursodiol300$41,554
Valganciclovir Hcl84$27,299
VemlidyTenofovir Alafenamide15$23,380
LokelmaSodium Zirconium Cyclosilicate25$22,412
ZarxioFilgrastim-Sndz25$20,020
Mycophenolate Mofetil160$19,834
VeltassaPatiromer Calcium Sorbitex19$18,883
Mycophenolic AcidMycophenolate Sodium41$13,807
EliquisApixaban15$13,213
Entecavir43$11,165
Cyclosporine ModifiedCyclosporine, Modified42$7,178
Tenofovir Disoproxil Fumarate52$6,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$278$23,38015 claims
AstraZenecaLokelma$184$22,41225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,830 surgery providers in Texas.

Other surgery in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →